VKTX 34.73 ▼ -1.11% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Viking Therapeutics Inc.

    NASDAQ: VKTX · Real-Time Price · USD
    34.73
    -0.39 (-1.11%)
    At close: Oct 16, 2025, 3:59 PM
    34.00
    -2.11%
    After-hours: Oct 16, 2025, 07:56 PM EDT
    -1.11%
    Bid 34.62
    Market Cap 3.91B
    Revenue (ttm) n/a
    Net Income (ttm) -171.55M
    EPS (ttm) -1.54
    PE Ratio (ttm) -22.55
    Forward PE -10.56
    Analyst Buy
    Dividends n/a
    Ask 34.84
    Volume 4,425,331
    Avg. Volume (20D) 6,463,181
    Open 35.59
    Previous Close 35.12
    Day's Range 34.16 - 36.80
    52-Week Range 18.92 - 81.73
    Beta 0.64
    Ex-Dividend Date n/a

    About VKTX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol VKTX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for VKTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    1 month ago
    -42.12%
    Viking Therapeutics shares are trading lower follo... Unlock content with Pro Subscription
    1 month ago
    -42.12%
    VKTX stock has given up its prior gain. Viking Therapeutics shares were trading higher after the company's obesity drug showed up to 12% weight loss in a Phase 2 trial.
    news image

    2 days ago · zacks.com

    Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note

    Viking Therapeutics, Inc. (VKTX) closed at $33.05 in the latest trading session, marking a -2.54% move from the prior day.

    news image

    1 week ago · seekingalpha.com

    Viking Therapeutics: A Speculative Buy

    Viking Therapeutics offers a de-risked, asymmetric investment opportunity in the GLP-1 weight-loss drug market, trading below its risk-adjusted potential. VKTX's injectable and oral VK2735 both met Ph...

    news image

    2 weeks ago · zacks.com

    Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know

    In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.88, denoting a +1.86% move from the preceding trading day.

    news image

    2 weeks ago · seekingalpha.com

    Viking Therapeutics: Overdue For Gains

    Viking Therapeutics trades at yearly lows despite being ahead of recently acquired competitor Metsera in the weight-loss drug race. The Metsera deal suggests up to 150% upside to Viking, especially wh...

    news image

    3 weeks ago · zacks.com

    Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

    In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.09, indicating a -5.78% shift from the previous trading day.

    news image

    3 weeks ago · zacks.com

    Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

    When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...

    news image

    3 weeks ago · zacks.com

    Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?

    VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.

    news image

    3 weeks ago · zacks.com

    Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know

    In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $24.97, denoting a -4.88% move from the preceding trading day.

    news image

    3 weeks ago · seekingalpha.com

    Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

    Viking Therapeutics, Inc. (NASDAQ:VKTX ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 11:20 AM EDT Company Participants Brian Lian - President, CEO & Director Conference Call P...

    news image

    3 weeks ago · seekingalpha.com

    Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

    Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2023 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Brian Lian - President and CEO Greg Zante - CFO Stephanie Diaz - Manager of I...

    Add to Watchlist